HR gene mutations have been proposed as prognostic markers for CRC patients undergoing chemotherapy (Lin et al. 2022), with MRE11 overexpression linked to poor OS in right-sided CRC (Ho et al. 2023; Naccarati et al. 2016). Here, HR is linked to colorectal carcinoma.